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I. Introduction
The American College of Cardiology/American Heart Asso-
ciation (ACC/AHA) Task Force on Practice Guidelines was
formed to gather information and make recommendations
about appropriate use of technology for the diagnosis and
treatment of patients with cardiovascular disease. Percutane-
ous coronary interventions (PCI) are an important group of
technologies in this regard. Although initially limited to
PTCA, and termed percutaneous transluminal coronary an-
gioplasty (PTCA), PCI now includes other new techniques
capable of relieving coronary narrowing. Accordingly, in this
document, rotational atherectomy, directional atherectomy,
extraction atherectomy, laser angioplasty, implantation of
intracoronary stents and other catheter devices for treating
coronary atherosclerosis are considered components of PCI.
In this context PTCA will be used to refer to those studies
using primarily PTCA while PCI will refer to the broader
group of percutaneous techniques. These new technologies
have impacted the effectiveness and safety profile initially
established for PTCA. Moreover, important advances have
occurred in the use of adjunctive medical therapies such as
glycoprotein (GP) IIb/IIIa receptor blockers. In addition,
since publication of the previous Guidelines in 1993, greater
experience in the performance of PCI in patients with acute
coronary syndromes and in community hospital settings has
been gained. In view of these developments, further review
and revision of the guidelines is warranted. This document
reflects the opinion of the third ACC/AHA committee
charged with revising the guidelines for PTCA to include the
broader group of technologies now termed PCI.
Several issues relevant to the Committee’s process and the
interpretation of the Guidelines have been noted previously
and are worthy of restatement. First, PCI is a technique that
has been continually refined and modified; hence continued,
periodic Guideline revision is anticipated. Second, these
guidelines are to be viewed as broad recommendations to aid
in the appropriate application of PCI. Under unique circum-
stances, exceptions may exist. These Guidelines are intended
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to complement, not replace, sound medical judgment and
knowledge. They are intended for operators who possess the
cognitive and technical skills for performing PCI and assume
that facilities and resources required to properly perform PCI
are available. As in the past, the indications are categorized as
Class I, II, or III based on a multifactorial assessment of risk
as well as expected efficacy viewed in the context of current
knowledge and the relative strength of this knowledge.
Initially, this document describes the background information
that forms the foundation for specific indications. Topics
fundamental to coronary intervention are reviewed followed
by separate discussions relating to unique technical and
operational issues. Formal recommendations for the use of
angioplasty are included in Section V. Indications are
organized according to clinical presentation. This format is
designed to enhance the usefulness of this document for the
assessment and care of patients with coronary artery disease
(CAD).
This document employs the ACC/AHA style classification
as Class I, II, or III. These classes summarize the indications
for PCI as follows:
Class I: Conditions for which there is evidence for
and/or general agreement that the procedure
or treatment is useful and effective.
Class II: Conditions for which there is conflicting evi-
dence and/or a divergence of opinion about
the usefulness/efficacy of a procedure or
treatment.
Class IIa: Weight of evidence/opinion is in
favor of usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well es-
tablished by evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that the procedure/treat-
ment is not useful/effective, and in some cases
may be harmful.
The weight of evidence in support of the recommendation
for each listed indication is presented as follows:
Level of Evidence A: Data derived from multiple ran-
domized clinical trials.
Level of Evidence B: Data derived from a single ran-
domized trial or nonrandomized
studies.
Level of Evidence C: Consensus opinion of experts.
The ACC/AHA Task Force on Practice Guidelines makes
every effort to avoid any actual or potential conflicts of
interest that might arise as a result of an outside relationship
or personal interest of a member of the writing panel.
Specifically, all members of the writing panel are asked to
provide disclosure statements of all such relationships that
might be perceived as real or potential conflicts of interest.
These statements are reviewed by the parent task force,
reported orally to all members of the writing panel at the first
meeting, and updated as changes occur.
II. General Considerations and Background
More than 500,000 PCI procedures are performed yearly in
the U.S., and it has been estimated that more than 1,000,000
procedures are performed annually worldwide. New coronary
devices have expanded the clinical and anatomical indica-
tions for revascularization initially limited by balloon catheter
angioplasty. For example, stents reduce both the acute risk of
major complications and late-term restenosis. The success of
new coronary devices in meeting these goals is in part
represented by the less frequent use of PTCA alone (,30%)
and the high (.70%) penetration of coronary stenting in the
current practice of interventional cardiology. Atherectomy
devices and stenting, associated with improved acute angio-
graphic and clinical outcomes compared to PTCA, in specific
subsets, continue to be applied to a wider patient domain that
includes multivessel disease and complex coronary anatomy.
However, strong evidence (level A data from multiple ran-
domized clinical trials) is only available for stenting in
selected patients undergoing single-vessel PCI. These Guide-
lines will focus on the Food and Drug Administration (FDA)
approved balloon-related and nonballoon coronary revascu-
larization devices.
III. Outcomes
The outcomes of coronary interventional procedures are
measured in terms of success and complications and are
related to the mechanisms of the employed devices, as well as
the clinical and anatomic patient-related factors. With in-
creased operator experience, new technology, and adjunctive
pharmacotherapy, the overall success and complication rates
of angioplasty have improved.
A. Definitions of PCI Success
The success of a PCI procedure may be defined by angio-
graphic, procedural, and clinical criteria.
1. Angiographic Success
A successful PCI produces substantial enlargement of the
lumen at the target site. The consensus definition prior to the
widespread use of stents was the achievement of a minimum
stenosis diameter reduction to ,50% in the presence of grade
3 TIMI flow (assessed by angiography). However, with the
advent of advanced adjunct technology, including coronary
stents, a minimum stenosis diameter reduction to ,20% has
been the clinical benchmark of an optimal angiographic
result.
2. Procedural Success
A successful PCI should achieve angiographic success with-
out in-hospital major clinical complications (e.g., death,
myocardial infarction [MI], emergency coronary artery by-
pass surgery [CABG]) during hospitalization. Although the
occurrence of emergency artery coronary bypass surgery and
death are easily identified end points, the definition of
procedure-related MI has been debated. The development of
Q-waves in addition to a threshold value of CK elevation has
been commonly used. However, the significance of enzyme
elevations in the absence of Q-waves remains a subject of
investigation and debate. Several reports have identified
non–Q-wave MIs with CK-MB elevations 3 to 5 times the
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upper limit of normal as having clinical significance. Thus a
significant increase in CK-MB without Q-waves is consid-
ered by most to qualify as an associated complication of PCI.
If serial determinations are performed after PCI, an abnor-
mally high value (CK-MB .1 times normal) can be expected
in 10 to 15% of PTCA procedures, 15 to 20% of stent
procedures, 25 to 35% of atherectomy procedures, and .25%
for any device used in saphenous vein grafts (SVGs) or long
lesions with a high atherosclerotic burden, even in the
absence of other signs and symptoms of MI. There is no
accepted consensus on what level of CK-MB index (with or
without clinical or electrocardiographic [ECG] findings) is
indicative of a clinically important MI following the inter-
ventional procedure. Cardiac troponin T and I have now been
introduced as measurements of myocardial necrosis and have
been proven to be more sensitive and specific than CK-MB.
However, prognostic criteria after PCI based on troponin T
and I have not yet been developed. The Writing Committee
recommends that CK-MB determination be performed on all
patients who have signs or symptoms suggestive of MI
following the procedure or in patients in whom there is
angiographic evidence of abrupt vessel closure, important side
branch occlusion, or new and persistent slow coronary flow. In
patients in whom a clinically driven CK-MB determination is
made, a CK-MB of .3 times the upper limit of normal would
constitute a clinically significant MI.
3. Clinical Success
In the short term, a clinically successful PCI includes ana-
tomic and procedural success with relief of signs and/or
symptoms of myocardial ischemia after the patient recovers
from the procedure. The long-term clinical success requires
that the short-term clinical success remains durable and that
the patient has persistent relief of signs and symptoms of
myocardial ischemia for more than 6 months after the
procedure. Restenosis is the principal cause of lack of
long-term clinical success when a short-term clinical success
has been achieved.
B. Definitions of Procedural Complications
As outlined in the 1998 coronary interventional document,
procedural complications are divided into six basic catego-
ries: death, MI, emergency CABG, stroke, vascular access
site complications, and contrast agent nephropathy. Key data
elements and definitions to measure the clinical management
and outcomes of patients undergoing diagnostic catheteriza-
tion and/or PCI have been defined in the Clinical Data
Standards document and the ACC-National Cardiovascular
Data Registry™ Catheterization Laboratory Module version
2.0. These rigorous definitions for key adverse events are
endorsed by this Writing Committee for inclusion in the
present PCI Guidelines (Table 1).
C. Acute Outcome
Improvements in balloon technology coupled with the in-
creased use of nonballoon devices, particularly stents (which
are effective in treating abrupt vessel closure) and GP IIb/IIIa
platelet receptor antagonists have favorably influenced acute
procedural outcome. This combined balloon/device/pharma-
cologic approach to coronary intervention in elective proce-
dures has resulted in angiographic success rates of 96 to 99%,
with Q-wave MI rates of 1 to 3%, emergency coronary bypass
surgery rates of 0.2 to 3%, and unadjusted in-hospital
mortality rates of 0.5 to 1.4%.
D. Long-Term Outcome and Restenosis
Although improvements in technology, including stents and
new pharmacologic therapy, have resulted in an improved
acute outcome of the procedure, the impact of these changes
on long-term (5 to 10 years) outcome may be less dramatic
where factors such as advanced age, reduced left ventricular
(LV) function, and complex multivessel disease in patients
currently undergoing PCI may have a more important influ-
ence. In addition, available data on long-term outcome are
mostly limited to patients undergoing PTCA. Ten-year
follow-up of the initial cohort of patients treated with PTCA
revealed an 89.5% survival rate (95% in patients with
single-vessel disease, 81% in patients with multivessel dis-
ease). In patients within the 1985–1986 NHLBI PTCA
Registry, 5-year survival was 92.9% for patients with single-
vessel disease, 88.5% for those with 2-vessel disease, and
86.5% for those with 3-vessel disease. In patients with
multivessel disease undergoing PTCA in BARI, 5-year sur-
vival was 86.3% and infarct-free survival was 78.7%. Specifi-
cally, 5-year survival was 84.7% in patients with 3-vessel
disease and 87.6% in patients with 2-vessel disease.
In addition to the presence of multivessel disease, other
clinical factors adversely impact late mortality. In random-
ized patients with treated diabetes in BARI, the 5-year
survival was 65.5%, and the cardiac mortality was 20.6% in
comparison to 5.8% cardiac mortality in patients without
treated diabetes, although among eligible but not randomized
diabetic patients, the 5-year cardiac mortality was 7.5%. In
the 1985–1986 NHLBI PTCA Registry, 4-year survival was
significantly lower in women (89.2%) in comparison to men
(93.4%). In addition, although LV dysfunction was not
associated with an increase in in-hospital mortality or nonfa-
tal MI in patients undergoing PTCA in the same registry, it
was an independent predictor of a higher long-term mortality.
A major determinant of event-free survival following
coronary intervention is the incidence of restenosis which
had, until the development of stents, remained fairly constant,
despite multiple pharmacologic and mechanical approaches
to limit this process (Table 2). Depending on the definition,
(i.e., whether clinical or angiographic restenosis or target
lesion revascularization is measured), the incidence of resten-
osis following coronary intervention had been 30 to 40%, and
higher in certain clinical and angiographic subsets.
Although multiple clinical factors (diabetes, unstable
angina, acute MI, prior restenosis), angiographic factors
(proximal left anterior descending artery, small vessel
diameters, total occlusion, long lesion length, SVG), and
procedural factors (higher post-procedure percent diameter
stenosis, smaller minimal lumen diameter, and smaller
acute gain), have been associated with an increased inci-
dence of restenosis, the ability to integrate these factors
and predict the risk of restenosis in individual patients
following the procedure remains difficult. The most prom-
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ising potential approaches to favorably impact the resten-
osis process relate to: 1) the ability to decrease elastic
recoil and remodeling using intracoronary stents, and 2) to
the ability to reduce intimal hyperplasia using catheter-
based ionizing radiation. More than 6,300 patients have
been studied in 12 randomized clinical trials to assess the
efficacy of PTCA vs. stents to reduce restenosis (Table 3).
In addition, randomized studies in patients with in-stent
restenosis have shown that both intracoronary gamma and
beta radiation significantly reduced the rate of subsequent
angiographic and clinical restenosis by 30 to 50%.
E. Predictors of Success/Complications
1. Anatomic Factors
The risk of PTCA in the pre-stent era relative to anatomic
subsets has been identified in previous NHLBI PTCA Registry
data and by the ACC/AHA Task Force. The lesion classification
based on severity of characteristics proposed in the past has been
principally altered using the present PCI techniques, which
capitalize on the ability of stents to manage initial and subse-
quent complications of coronary interventions. As a result the
Committee has revised the previous ACC/AHA lesion classifi-
cation system to reflect low, moderate, and high risk (Table 4) in
TABLE 1. Definitions of Procedural Complications
Procedural Complications Definitions
Primary cause of death Patient died during this hospitalization
Periprocedural MI The NEW presence of an MI as documented by at least 1 of the following criteria:
1. Evolutionary ST-segment elevations, development of new Q-waves in 2 or more contiguous ECG leads, or new or
presumably new LBBB pattern on the ECG
2. Biochemical evidence of myocardial necrosis; this can be manifested as 1) CK-MB $3 3 the upper limit of normal or
if CK-MB not available (2) total CK $3 3 upper limit of normal. Because normal limits of certain blood tests may
vary, please check with your lab for normal limits for CK-MB and total CK
CABG during this admission If the patient had a CABG during this admission indicate the CABG status using the following categories:
I. Elective: The procedure could be deferred without increased risk of compromised cardiac outcome
II. Urgent: All of the following conditions are met:
A. Not elective
B. Not emergency
C. Procedure required during same hospitalization in order to minimize chance of further clinical deterioration
III. Emergency: The patient’s clinical status includes any of the following:
A. Ischemic dysfunction (any of the following):
1. Ongoing ischemia including rest angina despite maximal medical therapy (medical and/or IABP)
2. Acute evolving MI within 24 hours before intervention
3. Pulmonary edema requiring intubation
B. Mechanical dysfunction (either of the following):
1. Shock with circulatory support
2. Shock without circulatory support
IV. Salvage: The patient is undergoing CPR en route to the Operating Room
CVA/Stroke Patient experienced a cerebrovascular accident (CVA) as documented by a loss of neurological function caused by an
ischemic event with residual symptoms at least 24 hours after onset
Vascular complications
Bleeding Blood loss at the site of arterial or venous access or due to perforation of a traversed artery or vein requiring transfusion
and/or prolonging the hospital stay, and/or causing a drop in hemoglobin .3.0 gm/dl. Bleeding attributable to the
vascular site could be retroperitoneal, a local hematoma .10 cm diameter or external
Occlusion A total obstruction of the artery usually at the site of access requiring surgical repair. Occlusion is defined as total
obstruction of the artery by thrombus, dissection or other mechanism, usually at the site of access, requiring surgical
repair. Occlusion may be accompanied by absence of palpable pulse or Doppler signal and associated with signs and
symptoms of an ischemic limb requiring surgical intervention
Dissection A dissection occurred at the site of percutaneous entry. Dissection is defined as disruption of an arterial wall resulting in
splitting and separation of the intimal (or subintimal) layers
Pseudoaneurysm Pseudoaneurysm is defined as the occurrence of an aneurysmal dilatation of the artery at the site of catheter entry
demonstrated by arteriography or ultrasound
AV fistula AV fistula is defined as a connection between the access artery (e.g., femoral) and access vein (e.g., femoral) that is
demonstrated by an imaging study (arteriography or ultrasound) and most often characterized by a continuous bruit
Renal failure After the lab visit—but before any subsequent lab visits only:
Indicate if the patient experienced acute renal insufficiency resulting in an increase in serum creatinine to more than 2.0
mg/dl (or a 50% or greater increase over an abnormal baseline) measured prior to procedure, or requiring dialysis
CABG 5 coronary artery bypass graft; CK 5 creatine kinase; CPR 5 cardiopulmonary resuscitation; ECG 5 electrocardiographic; IABP 5 intra-aortic balloon pump;
LBBB 5 left bundle-branch block; MI 5 myocardial infarction.
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accordance with the PCI Clinical Data Standards from the
ACC-National Cardiovascular Data Registry™.
2. Clinical Factors
Coexistent clinical conditions can increase the complication
rates for any given anatomic risk factor. The clinical risk
factors associated with in-hospital adverse events have been
further evaluated with additional experience during the PCI
era and summarized based on odds ratio .2.0 or results of
multivariate analysis (Table 5).
3. Risk of Death
In the majority of patients undergoing elective PCI, death as a
result of PCI is directly related to the occurrence of coronary
artery occlusion and is most frequently associated with pro-
TABLE 2. Selected Trials of Pharmacologic and Mechanical Approaches to Limit Restenosis
Study Year N Agent
Restenosis Rate (%)
Placebo or Control Agent
Schwartz 1988 376 Aspirin and Dipyridamole 39 38
Ellis 1989 416 Heparin 37 41
Pepine 1990 915 Methylprednislone 39 40
CARPORT 1991 649 Vapiprost 19 21
O’Keefe 1991 197 Colchicine 22 22
MERCATOR 1992 735 Cilazapril 28 28
CAVEAT* 1993 500 DCA vs. PTCA 57 50
CCAT 1993 136 DCA vs. PTCA 43 46
Serruys 1993 658 Ketanserin 32 32
BENESTENT* 1994 520 Stent vs. PTCA 32 22
ERA 1994 458 Enoxaparin 51 52
Leaf 1994 551 Fish Oil 46 52
STRESS* 1994 410 Stent vs. PTCA 42 32
Weintraub 1994 404 Lovastatin 42 39
BOAT* 1996 492 DCA vs. PTCA 40 31
Wantanabe* 1996 118 Probucol 40 20
Tardif* 1997 317 Probucol 39 21
BENESTENT II* 1998 823 Stent vs. PTCA 31 17
TREAT* 1999 255 Tranilast 39 18
PRESTO* 2000 192 DCA and Tranilast 26 11
*p , 0.05.
DCA 5 Directional Coronary Atherectomy; PTCA 5 percutaneous transluminal coronary angioplasty.
TABLE 3. Studies Comparing Balloon Angioplasty With Stents for Native Coronary Artery Lesions
Study Year
Follow-Up,
Month
N,
Stent/
Angioplasty
Angiographic Restenosis, %
Target-Vessel Revascularization
(TVR), %
Death, MI,
or TVR, %
Stent Angioplasty p Value Stent Angioplasty p Value Stent Angioplasty
STRESS 1994 6 205/202 31.6 42.1 0.046 10.2 15.4 0.06 19.5 23.8
BENESTENT* 1996 12 259/257 — — — 10 21 0.001 23.2 31.5
TASC I 1995 6 270 (Overall)† 31 46 0.01 — — — — —
Versaci et al. 1997 12 60/60 19 40 0.02 6.6 22 — — —
STRESS II 1998 12 100/89 — — — 10 20 — 17 34
BENESTENT II 1998 6 413/410 16 31 ,0.001 8‡ 13.7 0.02 12.8 19.3
OCBAS 1998 7 57/59 18.8 16.6 — 17.5 9.2 — 19.2 16.9
EPISTENT§ 1998 6 1603/796 — — — 8.7 15.4 ,0.001 13 20.5
START 1999 6/48\ 229/223 22 37 ,0.002 12 24.6 ,0.002 16.9 29.9
OPUS 2000 6 479 (Overall) — — — 3.0 10.1 0.003 6.1 14.9
*Any event at one year; †122 patients in the TASC I trial had treated restenotic lesions; ‡any repeat procedure; §stent plus abciximab vs. percutaneous transluminal
coronary angioplasty plus abciximab; \6 months angiographic follow-up and 48 months clinical follow-up.
MI 5 myocardial infarction; dashes (—) 5 data not reported for that category. Data are for lesions in coronary arteries with vessel diameter $3.0 mm. Adapted
from Suwaidi MB, et al. JAMA 2000;284:1828–36.
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nounced LV failure. The clinical and angiographic variables
associated with increased mortality include advanced age, fe-
male gender, diabetes, prior MI, multivessel disease, left main or
equivalent coronary disease, a large area of myocardium at risk,
pre-existing impairment of LV or renal function, and collateral
vessels supplying significant areas of myocardium that originate
distal to the segment to be dilated (Table 5).
4. Women
In comparison to men, women undergoing PCI are older and
have a higher incidence of hypertension, diabetes mellitus,
hypercholesterolemia, and comorbid disease. Early reports of
patients undergoing PTCA revealed a lower procedural suc-
cess rate in women; however, more recent studies have noted
similar angiographic outcome and incidence of MI and
emergency coronary bypass surgery in women and men.
Although reports have been inconsistent, in several large-
scale registries, in-hospital mortality is significantly higher in
women and an independent effect of gender on acute mortal-
ity following PCI persists after adjustments for the baseline
higher-risk profile in women.
5. The Elderly Patient
Age .75 years is one of the major clinical variables associ-
ated with increased risk of complications. In the elderly
population, the morphologic and clinical variables are com-
pounded by advanced years with the very elderly having the
highest-risk of adverse outcomes. In the stent era, procedural
success rates and short-term outcomes are comparable to
those for nonoctogenarians. Thus, with rare exception (pri-
mary PCI for cardiogenic shock for patients .75 years), a
separate category has not been created in these Guidelines for
the elderly. However, their higher incidence of comorbidities
should be taken into account when considering the need for
PCI.
6. Diabetes Mellitus
In the TIMI-IIB study of MI, patients with diabetes mellitus
had significantly higher 6-week (11.6% vs. 4.7%), 1-year
(18.0% vs. 6.7%), and 3-year (21.6% vs. 9.6%) mortality
rates compared to nondiabetic patients. The BARI trial, in
which stents and abciximab were not used, showed that
survival was better for patients with treated diabetes under-
going CABG with an arterial conduit than for those under-
going angioplasty. Stenting decreases the need for target
revascularization procedures in diabetic patients compared
with PTCA. The efficacy of stenting with GP IIb/IIIa inhib-
itors was assessed in the diabetic population compared to
those without diabetes in a substudy of the EPISTENT trial.
Irrespective of revascularization strategy abciximab signifi-
cantly reduced 6-month death and MI rates in patients with
diabetes for all strategies. Likewise, 6-month target-vessel
revascularization was reduced in the stent/abciximab group
approach.
7. Coronary Angioplasty After Coronary Artery
Bypass Surgery
Although speculated to be at higher risk, patients having PCI
of native vessels after prior coronary bypass surgery have, in
recent years, nearly equivalent interventional outcomes and
complication rates compared to patients having similar inter-
ventions without prior surgery. For PCI of SVG, studies
indicate that the rate of successful angioplasty exceeds 90%,
death ,1.2%, Q-wave MI ,2.5%. The incidence of non–Q-
wave MI may be higher than that associated with native
coronary arteries.
Use of GP IIb/IIIa blockers has not been shown to improve
results of angioplasty in vein grafts. The native vessels should
be treated with PCI if feasible. Patients with older and/or
severely diseased SVGs may benefit from elective repeat
coronary artery bypass graft surgery rather than PCI.
8. Specific Technical Considerations
Certain outcomes of PCI may be specifically related to the
technology utilized for coronary recanalization. Antecedent
unstable angina appears to be a clinical predictor of slow flow
and periprocedural infarction following ablative technologies
TABLE 4. Lesion Classification System
Anatomic Risk Groups*
2000
PCI Stent Era
Low Risk
Discrete (length ,10 mm)
Concentric
Readily accessible
Nonangulated segment (,45°)
Smooth contour
Little or no calcification
Less than totally occlusive
Not ostial in location
No major side branch involvement
Absence of thrombus
Moderate Risk
Tubular (length 10–20 mm)
Eccentric
Moderate tortuosity of proximal segment
Moderately angulated segment (.45°, ,90°)
Irregular contour
Moderate or heavy calcification
Total occlusions ,3 months old
Ostial in location
Bifurcation lesions requiring double guidewires
Some thrombus present
High Risk
Diffuse (length .20 mm)
Excessive tortuosity of proximal segment
Extremely angulated segments .90°
Total occlusions .3 months old and/or bridging collaterals
Inability to protect major side branches
Degenerated vein grafts with friable lesions
*This classification of lesion risk is cited from the ACC-National Cardiovas-
cular Data Registry™ Catheterization Laboratory Module version 2.0. This
classification scheme is also cited in the ACC Clinical Data Standards.
PCI 5 percutaneous coronary interventions.
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and direct platelet activation has been demonstrated to occur
with both directional and rotational atherectomy.
Coronary perforation may occur more commonly follow-
ing the use of ablative technologies including rotational,
directional or extraction atherectomy, and excimer laser
coronary angioplasty. Coronary perforation complicates PCI
more frequently in the elderly and in women. While 20% of
perforations may be secondary to the coronary guidewire,
most are related to the specific technology used.
9. Issues of Hemodynamic Support in
High-Risk Angioplasty
Elective high-risk PCI can be performed safely without
intra-aortic balloon pump (IABP) or cardiopulmonary sup-
port (CPS) in most circumstances. Emergency high-risk PCI
such as direct PCI for acute MI can usually be performed
without IABP or CPS. CPS for high-risk PCI should be
reserved only for patients at the extreme end of the spectrum
TABLE 5. Clinical Risk Factors Associated With In-Hospital Adverse Events*
Variables Definitions
Age Date of birth as stated by the patient or family
Gender Male or female
LVEF-calculated Calculated by LV gram, echo, blood pool scan
LVEF-estimated Estimated by LV gram, echo, blood pool scan
No. of vessels .70% By angiography measured, quantified or estimated diameter stenosis; “vessel” defined as RCA and its
branches, proximal LAD (before 1st diagonal), mid/distal LAD and its branches, and Cx and its branches
Unstable angina Progressive or new onset or occurs at rest accompanied by ECG changes, hypotension or pulmonary
congestion
CCS Class IV Highest CCS angina class leading to hospital admission and/or intervention: 0 5 no angina by Hx
CHF Hx of CHF before intervention
MI at this admission Within 24 h of AMI
Previous MI .1 day; ,7 days of AMI
Urgency of the procedure Elective: patient clinically stable; procedure routinely scheduled
Urgent: unstable patient: procedure scheduled before discharge
Emergent/ongoing ischemia: ongoing ischemia including rest angina despite maximal therapy (medical or
IABP)
Emergent/salvage: arrest with CPR immediately before entering lab
Cardiogenic shock Hypoperfusion with SBP ,80 mm Hg and central filling pressure .20 mm Hg or cardiac index
,1.8 liters/min/m2; also present if inotropes or IABP needed to maintain these values
Preprocedural IABP/CPS IABP/CPS assisted device placed before intervention
Aortic valve disease Aortic valve area ,1.0 cm2 and/or Aortic regurgitation .21
Mitral regurgitation .21 Presence of mitral regurgitation .21
Diabetes (treated) Clinical diagnosis of diabetes treated either with oral agents or insulin with or without sequelae
PVD Presence of occlusive disease in the aorta, iliac, or femoral artery sufficient to cause symptoms
Stroke Hx of presence of fixed neurological deficit
Creatinine If creatinine preintervention known, list creatinine
Creatinine .2 mg/dl Creatinine .2 mg/dl known in past
Dialysis Patient on dialysis
Cholesterol .225 mg/dl (reduced risk) Measure cholesterol . 225 mg/dl before intervention
Same vessel intervention (reduced risk) Any previous intervention on same vessel
Type C lesions attempted Type A: concentric noncalcified, ,10 mm in length, not bifurcated or angulated. Type C: total occlusion.
Type B: all others (ACC/AHA)
LMCA attempted-unprotected Intervention involving all or part of LMCA
LMCA attempted-protected “Protected” LMCA stenosis by patent bypass conduit
Vein graft intervention Any intervention to SVG or IMA
Thrombus Intraluminal filling defect, haziness or contrast staining in artery before intervention
*Note: More than 50% of databases that evaluated the variable showed an odds ratio .2.0 or variable chosen on multivariable analysis. The definition of variables
defined herein varies slightly from those agreed upon in the ACC Clinical Data Standards.
AMI 5 acute myocardial infarction; CCS 5 Canadian Cardiovascular Society; CHF 5 congestive heart failure; CPR 5 cardiopulmonary resuscitation; CPS 5
cardiopulmonary support; Cx 5 circumflex; ECG 5 electrocardiogram; Hx 5 history; IABP 5 intra-aortic balloon pump; IMA 5 internal mammary artery; LAD 5 left anterior
descending coronary artery; LMCA 5 left main coronary artery; LV 5 left ventricle; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction; PVD 5 peripheral
vascular disease; RCA 5 right coronary artery; SBP 5 systolic blood pressure; SVG 5 saphenous vein graft. Adapted with permission from Block P, et al. J Am Coll Cardiol.
2000;32:275–82.
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of hemodynamic compromise, such as those patients with
extremely depressed LV function and patients in cardiogenic
shock. However, it should be noted that in patients with
borderline hemodynamics, ongoing ischemia, or cardiogenic
shock, insertion of an intra-aortic balloon just prior to
coronary instrumentation has been associated with improved
outcomes. Furthermore, it is reasonable to obtain vascular
access in the contralateral femoral artery prior to the proce-
dure in patients in whom the risk of hemodynamic compro-
mise is high, thereby facilitating intra-aortic balloon inser-
tion, if necessary.
In patients having a higher-risk profile, consideration of
alternative therapies, particularly CABG, formalized surgical
standby, or periprocedural hemodynamic support should be
addressed before proceeding with PCI.
F. Comparison With Bypass Surgery
The major advantage of PCI is its relative ease of use,
avoiding general anesthesia, thoracotomy, extracorporeal cir-
culation, CNS complications, and prolonged convalescence.
Repeat PCI can be performed more easily than repeat bypass
surgery, and revascularization can be achieved more quickly
in emergency situations. The disadvantages of PCI are early
restenosis and the inability to relieve many totally occluded
arteries and/or those vessels with extensive atherosclerotic
disease.
Coronary artery bypass surgery has the advantages of
greater durability (graft patency rates exceeding 90% at 10
years with arterial conduits) and more complete revascular-
ization irrespective of the morphology of the obstructing
atherosclerotic lesion. Generally speaking, the greater the
extent of coronary atherosclerosis and its diffuseness, the
more compelling the choice of CABG, particularly if LV
function is depressed. Patients with lesser extent of disease
and localized lesions are good candidates for endovascular
approaches.
Percutaneous transluminal coronary angioplasty and
CABG have been compared in many nonrandomized and
randomized studies. The most accurate comparisons of out-
comes are best made from prospective randomized trials of
patients suitable for either treatment. Although results of
these trials provide useful information for selection of therapy
in several patient subgroups, prior studies of PTCA may not
reflect outcome of current PCI practice, which includes
frequent use of stents and antiplatelet drugs. Similarly, many
previous studies of CABG may not reflect outcome of current
surgical practice in which arterial conduits are used whenever
practicable. Beating heart bypass operations are also em-
ployed for selected patients with single-vessel disease with
reduced morbidity. In addition, patients are selected for PCI
(with or without stenting) because of certain lesion charac-
teristics, and these anatomical criteria are not required for
CABG.
Despite these limitations, some generalizations can be
made from comparative trials of PTCA and CABG. First, for
most patients with single-vessel disease, late survival is
similar with either revascularization strategy, and this might
be expected given the generally good prognosis of most
patients with single-vessel disease managed medically.
In the ARTS trial, the first trial to compare stenting with
surgery, there was no significant difference in mortality
between PCI and surgical groups at one year. The main
difference compared to previous PTCA and CABG trials was
an approximate 50% reduction in the need for repeat revas-
cularization in a group randomized to PCI with stent place-
ment.
Direct comparison of initial strategies of PCI or CABG in
patients with multivessel coronary disease is possible only by
randomized trials because of selection criteria of patients for
PCI. There have been five large (.300 patients) randomized
trials of PTCA versus CABG and two smaller studies. These
trials demonstrate that in appropriately selected patients with
multivessel coronary disease, an initial strategy of standard
PTCA yields similar overall outcomes (e.g., death, MI)
compared to initial revascularization with coronary artery
bypass.
An important exception to the conclusion of the relative
safety of PCI in multivessel disease is the subgroup of
patients with treated diabetes mellitus. Among treated dia-
betic patients in BARI assigned to PTCA, 5-year survival was
65.5% compared to 80.6% for patients having CABG (p 5
0.003); the improved outcome with CABG was due to
reduced cardiac mortality (5.8% vs. 20.6%, p 5 0.0003),
which was confined to those receiving at least one internal
mammary artery graft.
G. Comparison With Medicine
There has been a considerable effort made to evaluate the
relative effectiveness of bypass surgery as compared to PCI
for coronary artery revascularization. In contrast to this, very
little effort has been directed toward comparing medical
therapy with PCI for the management of stable and unstable
angina.
Based on the limited data available from randomized trials
(Table 6) comparing medical therapy with PTCA, it seems
prudent to consider medical therapy for the initial manage-
ment of most patients with Canadian Cardiovascular Society
Classification Class I and II and reserve PTCA and CABG for
those patients with more severe symptoms and ischemia. The
symptomatic individual patient who wishes to remain phys-
ically active, regardless of age, will more often require PCI.
The results of the ACIP trial indicate that higher-risk patients
with asymptomatic ischemia and significant CAD who un-
dergo complete revascularization with CABG or PTCA may
have a better outcome as compared to those with medical
management.
IV. Institutional and Operator Competency
A. Quality Assurance
A mechanism for valid peer review must be established and
ongoing at each institution performing PCI. Interventional
cardiology procedures are associated with complications that
in general are inversely related to operator and institutional
volume. The mechanism for institutional review should
provide an opportunity for interventionalists as well as
physicians who do not perform angioplasty, but are knowl-
edgeable about it, to review overall results of the program on
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TABLE 6. PCI Comparison With Medical Therapy
Study Year N Patient Population Treatment Follow-Up
Results
CommentsPCI
Medical
Therapy Significance
ACME 1992 212 Patients with single-
vessel disease
Medical therapy
vs. balloon
angioplasty
64% less
angina
46% less
angina
p , 0.01 The PTCA group had
less angina, better
exercise
performance and
more improvement
in quality of life
scores, but had
more complications
(emergency bypass
2 patients, MI in 5,
and repeat PTCA
in 16).
VA ACME 1997 328 Patients with
documented chronic
stable angina
Medical therapy
vs. balloon
angioplasty
3 years 63% less
angina
48% less
angina
p 5 0.02 Among patients with
single-vessel
disease, the PTCA
group had less
angina, better
exercise
performance, and
more improvement
in quality of life
scores.
227 single-vessel
disease
101 double-vessel
disease
RITA-2 1997 1018 53% with Class II
angina
47% with prior
angina
7% triple-vessel
disease
Medical therapy
vs. balloon
angioplasty
2.7 years 6.3% death
or MI
3.3% death or
MI
p 5 0.02 The PTCA group had
increased rates of
death and MI, but
had 7% less Class II
angina at 2 years
and longer exercise
treadmill test time at
3 months.
ACIP 1997 558 Patients with
documented CAD
and asymptomatic
ischemia
183 angina-guided
drug therapy
183 angina plus
ischemia-guided
drug therapy
192 revascularization
by PTCA or CABG
Angina-guided
drug therapy vs.
angina plus
ischemia-guided
drug therapy vs.
revascularization
2 years 4.7% death
or MI
8.8% death or
MI for
ischemia-
guided drug
therapy
12.1% death
or MI for
angina-guided
drug therapy
p , 0.01 40% of patients had
previous MI, 23%
had prior PTCA or
CABG and 38% had
triple-vessel disease.
AVERT 1999 341 Patients with stable
CAD, normal LV
function and angina
Class I/II
Medical therapy
with atorvastatin
vs PTCA
18 months 21%
ischemic
events
13% ischemic
events
p 5 0.048 p 5 0.045 needed
for significance due
to interim analysis.
Patients required to
complete 4 minutes
on Bruce protocol.
Only 2 deaths
among 341 patients
in 18 months.
Significant
improvement in
angina in patients
treated with PTCA
compared with
medical therapy.
CABG 5 coronary artery bypass graft; CAD 5 coronary artery disease; LV 5 left ventricular; MI 5 myocardial infarction; PCI 5 percutaneous coronary intervention;
PTCA 5 percutaneous transluminal coronary angioplasty.
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a regular basis. The responsible supervising authority should
monitor the following issues as outlined in Table 7.
The institutional credentialing committee should document
that an interventionalist wishing to start practice meets the
established training criteria, including those of the ACC Task
Force on Training in Cardiac Catheterization and Interven-
tional Cardiology. This Writing Committee agrees with the
ACC Task Force recommendations for the Assessment and
Maintenance of Proficiency in Coronary Interventional Pro-
cedures. Institutions performing PCI should meet the follow-
ing standards as outlined in Tables 8 and 9.
B. Operator and Institutional Volume
The proliferation of small angioplasty or small surgical
programs to support such angioplasty programs is strongly
discouraged. Several studies have identified procedural vol-
ume as a determining factor for frequency of complications
with PCI.
Although some investigators have suggested that low
procedure volume does not contribute to poor outcomes,
these studies are small in number and underpowered for
analysis. Development of small cardiovascular surgical pro-
grams to support angioplasty is a poor use of resources that
will likely lead to suboptimal results.
Given the concerns regarding operator volume and surgical
standby, it is recommended that PCI be performed by higher
volume operators ($75 cases/year) with advanced technical
skills (e.g., subspecialty certification) at institutions with fully
equipped interventional laboratories and experienced support
staff. This setting will most often be in a high-volume center
(.400 cases/year) associated with an on-site cardiovascular
surgical program. Similar concerns have been identified and
supported by the Task Force for Practice Guidelines for
Coronary Angiography.
This Committee acknowledges that not every cardiologist
desiring to do PCI should perform these procedures and not
every hospital anxious to have an interventional program
should start one. This caveat is particularly true where there
are high-volume programs and operators nearby. In these
situations, operators should be subspecialty board certified.
Recommendations for PCI Institutional and
Operator Volumes at Centers With On-Site
Cardiac Surgery
Class I
1. PCI done by operators with acceptable volume
(>75) at high-volume centers (>400). (Level of Evi-
dence: B)
Class IIa
1. PCI done by operators with acceptable volume
(>75) at low-volume centers (200 to 400). (Level of
Evidence: C)
2. PCI done by low volume operators (<75) at high-
volume centers (>400). Note: Ideally operators with
annual procedure volume <75 should only work at
institutions with an activity level of >600 proce-
dures/year.* (Level of Evidence: C)
Class III
1. PCI done by low volume operators (<75) at low-
volume centers (200 to 400). Note: An institution
with a volume <200 procedures/year, unless in a
region that is underserved because of geography,
TABLE 8. Considerations for the Assessment and Maintenance
of Proficiency in Coronary Interventional Procedures
Institutions
c Quality assessment monitoring of privileges and risk stratified outcomes
c Provide support for a quality assurance staff person (e.g., nurse) to
monitor complications
c Minimal institutional performance activity of 200 interventions per year
with the ideal minimum of 400 interventions per year
c Interventional program director who has a career experience of .500 PCI
procedures and is board certified by ABIM in interventional cardiology
c Facility and equipment requirements to provide high resolution fluoroscopy
and digital video processing
c Experienced support staff to respond to emergencies (See Section IV, C.
Need for Surgical Backup for discussion)
c Establishment of a mentoring program for operators who perform ,75
procedures per year by the individuals who perform $150 procedures per year
Physicians
c Procedural volume of $75 per year
c Continuation of privileges based on outcome benchmark rates with
consideration of not granting privileges to operators who exceed adjusted
case mix benchmark complication rates for a 2-year-period
c Ongoing quality assessment comparing results with current benchmarks
with risk stratification of complication rates
c Board Certification by ABIM in interventional cardiology
ABIM 5 American Board of Internal Medicine; PCI 5 percutaneous coronary
intervention.
TABLE 7. Key Components of a Quality Assurance Program
Clinical proficiency c General indications/contraindications
c Institutional and individual operator
complication rates, mortality and
emergency bypass surgery
c Institutional and individual operator
procedure volumes
c Training and qualifications of support
staff
Equipment maintenance
and management
c Quality of laboratory facility (See
ACC/SCA&I Expert Consensus
Document on Cardiac Catheterization
Laboratory Standards)
Quality improvement
process
c Establishment of an active
concurrent database to track clinical
and procedural information as well
as patient outcomes for individual
operators and the institution. The
ACC-National Cardiovascular Data
Registry™ is strongly recommended
for this purpose
Radiation safety c Educational program in the
diagnostic use of X-ray
c Patient and operator radiation
exposure
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should carefully consider whether it should continue
to offer service.* (Level of Evidence: C)
C. On-Site Cardiac Surgical Backup
Cardiac surgical backup for PCI has evolved from the formal
surgical standby in the 1980s to an informal arrangement of
first available operating room and, in some cases, off-site
surgical backup. With the advent of intracoronary stenting,
there has been a decrease in the need for emergency coronary
bypass, ranging between 0.4 and 2%.
1. Primary PCI Without On-Site Cardiac Surgery
Although thrombolytic trials demonstrated that early reper-
fusion saves myocardium and reduces mortality, the superi-
ority and greater applicability of primary PCI for the treat-
ment of acute MI has raised the question of whether primary
PCI should be performed at institutions with diagnostic
cardiac catheterization laboratories that do not perform elec-
tive PCI or have on-site cardiac surgery. For this reason, the
establishment of PCI programs at institutions without on-site
cardiovascular surgery has been promoted as necessary to
maintain quality of care. It must be realized that PCI in the
early phase of an acute MI can be difficult and requires even
more skill and experience than routine PCI in the stable
patient. The need for an experienced operator and experi-
enced laboratory technical support with availability of a
broad range of catheters, guidewires, stents, and other devices
(e.g., IABP) that are required for optimum results in an
acutely ill patient is of major importance (Table 9). If these
complex patients are treated by interventionalists with limited
experience at institutions with low volume, then the gains of
early intervention may be lost because of increased compli-
cations. In such circumstances, transfer to a center that
routinely performs complex PCI will often be a more effec-
tive and efficient course of action. Thrombolysis is still an
acceptable form of therapy and is preferable to acute PCI by
an inexperienced team.
Criteria have been suggested for the performance of
primary PCI at hospitals without on-site cardiac surgery
(Tables 9 and 10). Of note, large-scale registries have shown
an inverse relationship between the number of primary
angioplasty procedures performed and in-hospital mortality.
The data suggest that both door-to-balloon time and in-
hospital mortality are significantly lower in institutions per-
forming a minimum of 36 primary angioplasty procedures per
year. Communities may identify a unique qualified and
experienced center wherein the on-site intervention for acute
MI could be performed. Suboptimal results may relate to
operator/staff inexperience and capabilities and delays in
performing angioplasty for logistical reasons. From clinical
data and expert consensus, the Committee recommends that
primary PCI for acute MI performed at hospitals without
established elective PCI programs should be restricted to
those institutions with a proven plan for rapid and effective
PCI as well as rapid access to cardiac surgery in a nearby
facility (Table 11).
2. Elective PCI Without On-Site Surgery
Technical improvements in interventional cardiology have
led to the development of elective angioplasty programs
without on-site surgical coverage. Caution is warranted be-
fore endorsing an unrestricted policy for PCI in hospitals
without appropriate facilities. Several outstanding and criti-
cally important clinical issues, such as timely management of
ischemic complications, adequacy of specialized post-
interventional care, logistics for managing cardiac surgical or
vascular complications and operator/laboratory volumes, and
accreditation must be addressed. At this time, the Committee,
therefore, continues to support the recommendation that
elective PCI should not be performed in facilities without
on-site cardiac surgery (Table 11). As with many dynamic
areas in interventional cardiology, these recommendations
may be subject to revision as clinical data and experience
increase.
*Operators who perform ,75 procedures/year should develop a
defined mentoring relationship with a highly experienced operator who
has an annual procedural volume .150 procedures/year.
TABLE 9. Criteria for the Performance Angioplasty at
Hospitals Without On-Site Cardiac Surgery
1. The operators must be experienced interventionalists who regularly
perform elective intervention at a surgical center ($75 cases/year). The
institution must perform a minimum of 36 primary PCI procedures per
year.
2. The nursing and technical catheterization laboratory staff must be
experienced in handling acutely ill patients and comfortable with
interventional equipment. They must have acquired experience in
dedicated interventional laboratories at a surgical center. They
participate in a 24-h, 365-day call schedule.
3. The catheterization laboratory itself must be well-equipped, with optimal
imaging systems, resuscitative equipment, intra-aortic. balloon pump
(IABP) support, and must be well-stocked with a broad array of
interventional equipment.
4. The cardiac care unit nurses must be adept in hemodynamic monitoring
and IABP management.
5. The hospital administration must fully support the program and enable
the fulfillment of the above institutional requirements.
6. There must be formalized written protocols in place for immediate
(within 1 h) and efficient transfer of patients to the nearest cardiac
surgical facility which are reviewed/tested on a regular (quarterly) basis.
7. Primary intervention must be performed routinely as the treatment of
choice around the clock for a large proportion of patients with AMI, to
ensure streamlined care paths and increased case volumes.
8. Case selection for the performance of primary angioplasty must be
rigorous. Criteria for the types of lesions appropriate for primary
angioplasty and for the selection for transfer for emergent aortocoronary
bypass surgery are shown in Table 10.
9. There must be an ongoing program of outcomes analysis and
formalized periodic case review.
10. Institutions should participate in a 3- to 6-month period of
implementation during which time development of a formalized primary
PCI program is instituted that includes establishing standards, training
staff, detailed logistic development, and creation of a quality
assessment and error management system.
Adapted with permission from Wharton TP Jr, McNamara NS, Fedele FA,
Jacobs MI, Gladstone AR, Funk EJ. Primary angioplasty for the treatment of
acute myocardial infarction: experience at two community hospitals without
cardiac surgery. J Am Coll Cardiol 1999;33:1257–65.
AMI 5 acute myocardial infarction; IABP 5 intra-aortic balloon pump; PCI 5
percutaneous coronary intervention.
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Recommendations for PCI With and Without
On-Site Cardiac Surgery (Table 11)
Class I
1. Patients undergoing elective PCI in facilities with
on-site cardiac surgery. (Level of Evidence: B)
2. Patients undergoing primary PCI in facilities with
on-site cardiac surgery. (Level of Evidence: B)
Class IIb
1. Patients undergoing primary PCI in facilities with-
out on-site cardiac surgery, but with a proven plan
for rapid access (within 1 h) to a cardiac surgery
operating room in a nearby facility with appropriate
hemodynamic support capability for transfer. The
procedure should be limited to patients with ST-
segment elevation MI or new LBBB on ECG, and
done in a timely fashion (balloon inflation within
90 6 30 min of admission) by persons skilled in the
procedure (>75 PCIs/year) and only at facilities
performing a minimum of 36 primary PCI proce-
dures per year. (Level of Evidence: B)
Class III
1. Patients undergoing elective PCI in facilities without
on-site cardiac surgery. (Level of Evidence: C)
2. Patients undergoing primary PCI in facilities with-
out on-site cardiac surgery and without a proven plan
for rapid access (within 1 h) to a cardiac surgery
operating room in a nearby facility with appropriate
hemodynamic support capability for transfer or when
performed by lower skilled operators (<75 PCIs/year)
in a facility performing <36 primary PCI procedures
per year. (Level of Evidence: C)
V. Indications
A broad spectrum of clinical presentations exists wherein
patients may be considered candidates for PCI, ranging from
asymptomatic to severely symptomatic or unstable, with
variable degrees of jeopardized myocardium. Each time that
a patient is considered for revascularization, the potential risk
and benefits of the particular procedure under consideration
must be weighed against alternative therapies.
The initial simplicity and associated low morbidity of PCI
as compared to surgical therapy is always attractive, but the
patient and family must understand the limitations inherent in
TABLE 10. Patient Selection for Angioplasty and Emergency
Aortocoronary Bypass at Hospitals Without On-Site
Cardiac Surgery
Avoid intervention in hemodynamically stable patients with:
c Significant ($60%) stenosis of an unprotected left main (LM) coronary
artery upstream from an acute occlusion in the left coronary system that
might be disrupted by the angioplasty catheter
c Extremely long or angulated infarct-related lesions with TIMI grade 3 flow
c Infarct-related lesions with TIMI grade 3 flow in stable patients with
3-vessel disease
c Infarct-related lesions of small or secondary vessels
c Lesions in other than the infarct artery
Transfer for emergent aortocoronary bypass surgery patients with:
c High-grade residual left main or multivessel coronary disease and clinical
or hemodynamic instability
—After angioplasty or occluded vessels
—Preferably with intraaortic balloon pump support
Adapted with permission from Wharton TP Jr, McNamara NS, Fedele FA,
Jacobs MI, Gladstone AR, Funk EJ. Primary angioplasty for the treatment of
acute myocardial infarction: experience at two community hospitals without
cardiac surgery. J Am Coll Cardiol 1999;33:1257–65.
TABLE 11. Recommendations For PCI With and Without On-Site Cardiac Surgery
With On-Site Cardiac Surgery Without On-Site Cardiac Surgery
Elective PCI Class I Class III
Patients undergoing elective PCI in facilities with on-site
cardiac surgery.
Patients undergoing elective PCI in facilities without on-site cardiac surgery.
(Level of Evidence: B) (Level of Evidence: C)
Primary PCI Class I Class IIb
Patients undergoing primary PCI in facilities with on-site
cardiac surgery.
(Level of Evidence: B)
Patients undergoing primary PCI in facilities without on-site cardiac surgery,
but with a proven plan for rapid access (within 1 h) to a cardiac surgery
operating room in a nearby facility with appropriate hemodynamic support
capability for transfer. The procedure should be limited to patients with
ST-segment elevation MI or new LBBB on ECG, and done in a timely fashion
(balloon inflation within 90 6 30 min of admission) by persons skilled in the
procedure ($75 PCIs/year) and only at facilities performing a minimum of 36
primary PCI procedures per year.
(Level of Evidence: B)
Class III
Patients undergoing primary PCI in facilities without on-site cardiac surgery
and without a proven plan for rapid access (within 1 h) to a cardiac surgery
operating room in a nearby facility with appropriate hemodynamic support
capability for transfer.
(Level of Evidence: C)
ECG 5 electrocardiography; LBBB 5 left bundle-branch block; MI 5 myocardial infarction; PCI 5 percutaneous coronary intervention.
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current PCI procedures, including a realistic presentation of
the likelihood of restenosis and the potential for incomplete
revascularization as compared with CABG surgery. In pa-
tients with CAD who are asymptomatic or have only mild
symptoms, the potential benefit of antianginal drug therapy
along with an aggressive program of risk reduction must also
be understood by the patient before a revascularization
procedure is performed.
A. Asymptomatic or Mild Angina
In the previous ACC/AHA Guidelines for PTCA, specific
recommendations were made separately for patients with
single- or multivessel disease. The current techniques of
PCI have matured to the point where, in patients with
favorable anatomy, the competent practitioner can perform
either single- or multivessel PCI at low risk and with a
high likelihood of initial success. For this reason, in this
revision of the Guidelines, recommendations will be made
largely based upon the patients’ clinical condition, specific
coronary lesion morphology and anatomy, LV function,
and associated medical conditions, and less emphasis will
be placed on the number of lesions or vessels requiring
PCI. The CCS Class of angina (I to IV) is used to define
the severity of symptoms. The categories described in this
section refer to an initial PCI procedure in a patient
without prior CABG surgery.
The Committee recognizes that the majority of patients
with asymptomatic ischemia or mild angina should be treated
medically. The published ACIP study casts some doubt on the
wisdom of medical management for those higher-risk patients
who are asymptomatic or have mild angina, but have objec-
tive evidence by both treadmill testing and ambulatory
monitoring of significant myocardial ischemia and CAD. In
addition, there is a substantial portion of the middle and older
age populations in this country that remains physically active,
participating in sports, such as tennis and skiing, or perform-
ing regular and vigorous physical exercise, such as jogging,
who have CAD. For such individuals with moderate or severe
ischemia and few symptoms, revascularization with PCI or
CABG surgery may reduce their risk of serious or fatal
cardiac events. For this reason, patients in this category of
higher-risk asymptomatic ischemia or mild symptoms and
severe anatomic CAD are placed in Class I or II. PCI may be
considered if there is a high likelihood of success and a low
risk of morbidity or mortality. The judgment of the experi-
enced physician is deemed valuable in assessing the extent of
ischemia.
Recommendations for PCI in Asymptomatic or
Class I Angina Patients
Class I
1. Patients who do not have treated diabetes with
asymptomatic ischemia or mild angina with 1 or
more significant lesions in 1 or 2 coronary arteries
suitable for PCI with a high likelihood of success and
a low risk of morbidity and mortality. The vessels to be
dilated must subtend a large area of viable myocar-
dium (Table 12). (Level of Evidence: B)
Class IIa
1. The same clinical and anatomic requirements for
Class I, except the myocardial area at risk is of
moderate size or the patient has treated diabetes.
(Level of Evidence: B)
Class IIb
1. Patients with asymptomatic ischemia or mild angina
with >3 coronary arteries suitable for PCI with a
high likelihood of success and a low risk of morbidity
and mortality. The vessels to be dilated must sub-
tend at least a moderate area of viable myocardium.
In the physician’s judgment, there should be evi-
dence of myocardial ischemia by ECG exercise
testing, stress nuclear imaging, stress echocardiogra-
phy or ambulatory ECG monitoring, or intracoronary
physiologic measurements. (Level of Evidence: B)
Class III
1. Patients with asymptomatic ischemia or mild angina
who do not meet the criteria as listed under Class I
or Class II and who have:
a. Only a small area of viable myocardium at
risk.
b. No objective evidence of ischemia.
c. Lesions that have a low likelihood of success-
ful dilation.
d. Mild symptoms that are unlikely to be due to
myocardial ischemia.
e. Factors associated with increased risk of mor-
bidity or mortality.
f. Left main disease.
g. Insignificant disease <50%. (Level of Evi-
dence: C)
B. Angina Class II to IV or Unstable Angina
Many patients with moderate or severe stable angina or
unstable angina do not respond adequately to medical therapy
and often have significant coronary artery stenoses that are
suitable for revascularization with CABG surgery or PCI. In
addition, a proportion of these patients have reduced LV
systolic function which places them in a group that is known
to have improved survival with CABG surgery and possibly
TABLE 12. Noninvasive Risk Stratification: High Risk (>3%
Annual Mortality Rate)
c High-risk treadmill score (score #-11)
c Stress-induced large perfusion defect (particularly if anterior)
c Stress-induced perfusion defects of moderate size
c Stress-induced multiple perfusion defect with LV dilation or increased
lung uptake (thallium-201)
c Echocardiographic wall motion abnormality (involving .2 segments)
developing at a low dose of dobutamine (#10 mg z kg21 z min21) or at a
low heart rate (120 bpm)
c Stress echocardiographic evidence of extensive ischemia
Adapted with permission from Gibbons RJ, Chatterjee K, Daley J, et al.
ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic
stable angina. J Am Coll Cardiol 1999;33:2092–197.
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with revascularization by PCI. In nondiabetic patients with 1-
or 2-vessel disease in whom angioplasty of 1 or more lesions
has a high likelihood of initial success, PCI is the preferred
approach. In a minority of such patients, CABG surgery may
be preferred, particularly for those in whom the left anterior
descending coronary artery can be revascularized with the
internal mammary artery or in those with left main coronary
disease. In patients with unstable angina or non–Q-wave MI,
intensive medical therapy should be initiated prior to revas-
cularization with PCI or CABG surgery. Patients with unsta-
ble angina and non–ST-segment elevation MI have been
randomized to medical therapy or PCI in the FRISC II and
TACTICS TIMI 18 trials. These trials utilizing stenting as the
primary therapy have favored the invasive approach.
The indications for coronary angiography are summarized
in the ACC/AHA Coronary Angiography Guidelines and
recommendations for PCI are summarized in the ACC/AHA
Unstable Angina Guidelines. Indications for PCI for patients
with angina Class II to IV, unstable angina, or non–Q-wave
infarction follow.
Recommendations for Patients With Moderate or
Severe Symptoms (Angina Class II to IV, Unstable
Angina or Non–ST-Elevation MI) With Single- or
Multivessel Coronary Disease on Medical Therapy
Class I
1. Patients with 1 or more significant lesions in 1 or
more coronary arteries suitable for PCI with a high
likelihood of success and low risk of morbidity or
mortality (Table 5). The vessel(s) to be dilated must
subtend a moderate or large area of viable myocar-
dium and have high risk (Table 12). (Level of
Evidence: B)
Class IIa
1. Patients with focal saphenous vein graft lesions or
multiple stenoses who are poor candidates for reop-
erative surgery. (Level of Evidence: C)
Class IIb
1. Patient has 1 or more lesions to be dilated with
reduced likelihood of success (Table 5) or the ves-
sel(s) subtend a less than moderate area of viable
myocardium. Patients with 2- or 3-vessel disease,
with significant proximal LAD CAD and treated
diabetes or abnormal LV function. (Level of Evi-
dence: B)
Class III
1. Patient has no evidence of myocardial injury or
ischemia on objective testing and has not had a trial
of medical therapy, or has:
a. Only a small area of myocardium at risk.
b. All lesions or the culprit lesion to be dilated
with morphology with a low likelihood of
success.
c. A high risk of procedure-related morbidity
or mortality. (Level of Evidence: C) T
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2. Patients with insignificant coronary stenosis (e.g.,
<50% diameter). (Level of Evidence: C)
3. Patients with significant left main CAD who are
candidates for CABG. (Level of Evidence: B)
It is recognized by the Committee that the assessment of
risk of unsuccessful PCI or serious morbidity or mortality
must always be made with consideration of the alternative
therapies available for the patient, including more intensive or
prolonged medical therapy or surgical revascularization (Ta-
ble 13), especially in patients with unstable angina pectoris.
When CABG surgery is a poor option because of high risk
due to special considerations or other organ system disease,
patients otherwise in Class IIb may be appropriately managed
with PCI. Under these special circumstances formal surgical
consultation is recommended.
C. Myocardial Infarction
The results of randomized clinical trials of intravenous
thrombolysis and subsequent management strategies of im-
mediate, delayed, and deferred PCI have established the
benefits of early pharmacologic and mechanical reperfusion
therapies for patients with acute MI.
Percutaneous coronary intervention is a very effective
method for re-establishing coronary perfusion and is suitable
for $90% of patients. Considerable data support the use of
PCI for patients with acute MI. Reported rates of achieving
TIMI 3 flow, the goal of reperfusion therapy, range from 70
to 90%. Late follow-up angiography demonstrates that 87%
of infarct arteries remain patent. Although most evaluations
of PCI have been in patients who are eligible to receive
thrombolytic therapy, considerable experience supports the
value of PCI for patients who may not be suitable for
thrombolytic therapy due to an increased risk of bleeding.
Intracoronary stents appear to augment the results of PCI
for MI (Table 14). Preliminary results suggest that stenting
achieves a better immediate angiographic result with a larger
arterial lumen, less reclosure of the infarct-related artery, and
fewer subsequent ischemic events than PTCA alone. Results
from a randomized clinical trial suggest that stenting en-
hances late clinical outcomes (reduction in composite end
point attributable to a decrease in target-vessel revasculariza-
tion) when compared to PTCA alone. However an increase in
mortality at 1 year among the stent group has been reported
in the Stent-PAMI trial.
Primary PTCA performed without routine stenting has
been compared to thrombolytic therapy in several random-
ized clinical trials. These investigations consistently demon-
strate that PTCA-treated patients experience less recurrent
ischemia or infarction than those treated by thrombolysis.
Trends favoring a survival benefit with PTCA are noted. Two
meta-analyses showed superiority of PCI over thrombolysis
for mortality with risk reductions of 0.34 and 0.56. It is
important to note that these results of PCI have been achieved
in medical centers with experienced providers and under
circumstances where angioplasty can be performed immedi-
ately following patient presentation.
1. PCI in Thrombolytic-Ineligible Patients
Randomized, controlled clinical trials evaluating the outcome
of PCI for patients who present with ST-segment elevation
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but who are ineligible for thrombolytic therapy and for
patients who experience infarction without ST-segment ele-
vation have not been performed. Nevertheless, there is a
general consensus that PCI is an appropriate means for
achieving reperfusion in patients who cannot receive throm-
bolytics because of increased risk of hemorrhage. Other
reasons also exclude acute MI patients from thrombolytic
therapy and the outcome of PCI in these patients may differ
from those eligible for lytic therapy. For example, patients
who present without ST-elevation are more often older and
female and have higher in-hospital mortality than those with
ST-segment elevation. Little data are available to characterize
the value of primary PCI for this subset of acute MI patients
(Table 15).
2. Post-Thrombolysis PCI
In asymptomatic patients, the strategies of routine PCI of the
stenotic infarct-related artery immediately after successful
thrombolysis show no benefit with regard to salvage of
jeopardized myocardium or prevention of reinfarction or
death. In some studies this approach was associated with
increased incidence of adverse events, which include bleed-
ing, recurrent ischemia, emergency coronary artery surgery,
and death. Routine PCI immediately after thrombolysis may
increase the chance for vascular complications at the cathe-
terization access site and hemorrhage into the infarct-related
vessel wall.
3. Rescue PCI
Rescue (also known as salvage) PCI is defined as PCI after
failed thrombolysis for patients with continuing or recurrent
myocardial ischemia. Rescue PCI has resulted in higher rates
of early infarct-artery patency, improved regional infarct zone
wall motion, and greater freedom from adverse in-hospital
clinical events compared to a deferred PCI strategy. The
randomized evaluation of rescue PCI with combined utiliza-
tion end points trial (RESCUE) demonstrated a reduction in
rates of in-hospital death and combined death and congestive
heart failure maintained up to 1 year after study entry for
patients presenting with anterior wall MI who failed throm-
bolytic therapy. Improvement in TIMI grade flow from #2 to
3 may offer additional clinical benefit.
4. PCI for Cardiogenic Shock
Observational studies support the value of PCI for patients
who develop cardiogenic shock in the early hours of MI. For
patients who do not have mechanical causes of shock, such as
acute mitral regurgitation or septal or free wall rupture,
mortality among those having PCI is lower than those treated
by medical means.
A randomized clinical trial has further clarified the role of
emergency revascularization (ERV) in acute MI complicated
by cardiogenic shock. This multicenter trial supports the use
of ERV with PCI in appropriate candidates for patients ,75
years old with acute MI complicated by cardiogenic shock.
After 6 months, there was significant survival benefit to early
revascularization. These data strongly support the approach
that patients ,75 years with acute MI complicated by
cardiogenic shock should undergo emergency revasculariza-
tion and support measures.
5. PCI Hours to Days After Thrombolysis
Patients who achieve reperfusion and myocardial salvage
following thrombolytic therapy may experience reocclusion
of the infarct artery and recurrent MI. This concern has
prompted the routine use of catheterization and PCI prior to
hospital discharge to identify and dilate the culprit lesion. The
SWIFT study examined 800 patients with acute MI randomly
assigned to PCI within 2 to 7 days after thrombolysis or to
conservative management with intervention for spontaneous
or provocable ischemia. There were no differences in the two
treatment strategies regarding LV function, incidence of
reinfarction, in-hospital survival, or 1-year survival rate.
These data indicate that routine PCI of the infarct-related
artery in the absence of spontaneous or provoked ischemia is
not warranted.
Initial studies of late (.6 to 12 h) PCI in asymptomatic
survivors of MI indicate that opening an occluded artery does
not appear to alter the process of LV dilation, the incidence of
spontaneous and inducible arrhythmias, or prognosis. Al-
though data supporting the argument to open occluded
infarct-related arteries are persuasive, at least for large arter-
ies subtending large areas of myocardium, there are few
randomized trials supporting this approach. It should be noted
that the overwhelming majority of trials were performed prior
TABLE 15. Contraindications and Cautions for Thrombolytic
Use in Myocardial Infarction*
Contraindications
c Previous hemorrhagic stroke at any time, other strokes or cerebrovascular
events within 1 year
c Known intracranial neoplasm
c Active internal bleeding (does not include menses)
c Suspected aortic dissection
Caution/relative contraindications
c Severe uncontrolled hypertension on presentation (blood pressure
.180/110 mm Hg)†
c History of prior cerebrovascular accident or known intracerebral pathology
not covered in contraindications
c Current use of anticoagulants in therapeutic doses (INR $2–3); known
bleeding diathesis
c Recent trauma (within 2–4 weeks) including head trauma or traumatic or
prolonged (.10 min) CPR or major surgery (3 weeks)
c Noncompressible vascular punctures
c Recent (within 2 to 4 weeks) internal bleeding
c For streptokinase/anistreplase: prior exposure (especially within 5 days–2
years) or prior allergic reaction
c Pregnancy
c Active peptic ulcer
c History of chronic severe hypertension
*Viewed as advisory for clinical decision making and may not be all-inclusive
or definitive; †Could be an absolute contraindication in low-risk patients with
myocardial infarction.
INR 5 International Normalized Ratio; CPR 5 cardiopulmonary resuscitation.
Reproduced with permission from Ryan TJ, Antman EM, Brooks NH, et al.
ACC/AHA guidelines for the management of patients with acute myocardial
infarction: a report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Committee on Management of
Acute Myocardial Infarction). J Am Coll Cardiol 1999;34:890–911.
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to the widespread use of stents and platelet IIb/IIIa receptor
blockade and thus, the potential impact and benefit of these
newer therapies in this clinical setting needs re-evaluation.
6. PCI After Thrombolysis in Selected Patient Subgroups
a. Young and Elderly Post-Infarct Patients
Although not supported by randomized trials, routine cardiac
catheterization following thrombolytic therapy for AMI has
been a frequently performed strategy in all age groups. Young
(,50 years) patients often undergo cardiac catheterization
after thrombolytic therapy due to a “perceived need” to define
coronary anatomy and thus establish psychological as well as
clinical outcomes. In contrast, older (.75 years) patients
have higher in-hospital and long-term mortality rates and
enhanced clinical outcomes when treated with primary PCI.
Confirmatory studies to determine quality-of-life aspects of
care in younger patients and to define the potential of other
modes of coronary revascularization in older patient groups
are not yet available. Based on the current data, with the
exception of patients presenting with cardiogenic shock, PCI
should be based on clinical need without special consider-
ation of age.
b. Patients With Prior Myocardial Infarction
A prior MI is an independent predictor of death, reinfarction,
and need for urgent coronary bypass surgery. In the TIMI-II
study, patients with a history of prior MI had a higher 42-day
mortality (8.8% vs. 4.3%; p , 0.001), higher prevalence of
multivessel CAD (60% vs. 28%; p , 0.001), and a lower LV
ejection fraction (42% vs. 48%; p , 0.001) compared to
patients with a first MI. Mortality tended to be lower among
patients with a prior MI undergoing the invasive compared to
the conservative strategy, a benefit which persisted up to 1
year following study entry.
Based on the earlier findings in this document and current
practice, PCI should be based on clinical need. The presence
of prior MI places the patient in a higher risk subset and
should be considered in the PCI decision.
Recommendations for Primary PCI for Acute
Transmural MI Patients as an Alternative
to Thrombolysis
Class I
1. As an alternative to thrombolytic therapy in patients
with AMI and ST-segment elevation or new or
presumed new left bundle branch block who can
undergo angioplasty of the infarct artery <12 h
from the onset of ischemic symptoms or >12 h if
symptoms persist, if performed in a timely fashion*
by individuals skilled in the procedure† and sup-
ported by experienced personnel in an appropriate
laboratory environment.‡ (Level of Evidence: A)
2. In patients who are within 36 h of an acute ST
elevation/Q-wave or new left bundle branch block
MI who develop cardiogenic shock, are <75 years of
age, and revascularization can be performed within
18 h of the onset of shock by individuals skilled in the
procedure† and supported by experienced personnel
in an appropriate laboratory environment.‡ (Level
of Evidence: A)
Class IIa
1. As a reperfusion strategy in candidates who have a
contraindication to thrombolytic therapy. (Level of
Evidence: C)
Class III
1. Elective PCI of a non–infarct-related artery at the
time of acute MI. (Level of Evidence: C)
2. In patients with acute MI who:
a. have received fibrinolytic therapy within
12 h and have no symptoms of myocardial
ischemia.
b. are eligible for thrombolytic therapy and are
undergoing primary angioplasty by an inex-
perienced operator (individual who performs
<75 PCI procedures/year).
c. are beyond 12 h after onset of symptoms and
have no evidence of myocardial ischemia.
(Level of Evidence: C)
Recommendations for PCI After Thrombolysis
Class I
1. Objective evidence for recurrent infarction or isch-
emia (rescue PCI). (Level of Evidence: B)
Class IIa
1. Cardiogenic shock or hemodynamic instability.
(Level of Evidence: B)
Class IIb
1. Recurrent angina without objective evidence of isch-
emia/infarction. (Level of Evidence: C)
2. Angioplasty of the infarct-related artery stenosis
within hours to days (48 h) following successful
thrombolytic therapy in asymptomatic patients
without clinical and/or inducible evidence of isch-
emia. (Level of Evidence: B)
Class III
1. Routine PCI within 48 h following failed thrombol-
ysis. (Level of Evidence: B)
2. Routine PCI of the infarct-artery stenosis immedi-
ately after thrombolytic therapy. (Level of Evidence: A)
Recommendations for PCI During Subsequent Hospital
Management After Acute Therapy for AMI Including
Primary PCI
Class I
1. Spontaneous or provocable myocardial ischemia dur-
ing recovery from infarction. (Level of Evidence: C)
2. Persistent hemodynamic instability. (Level of Evi-
dence: C)
Class IIa
1. Patients with LV ejection fraction <0.4, CHF, or
serious ventricular arrhythmias. (Level of Evidence: C)
*Performance standard: balloon inflation within 90 (630) min of
hospital admission; †Individuals who perform $75 PCI procedures/year;
‡Centers that perform .200 PCI procedures/year and have cardiac
surgical capability.
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Class IIb
1. Coronary angiography and angioplasty for an oc-
cluded infarct-related artery in an otherwise stable
patient to revascularize that artery (open artery
hypothesis). (Level of Evidence: C)
2. All patients after a non–Q-wave MI. (Level of Evi-
dence: C)
3. Clinical HF during the acute episode, but subse-
quent demonstration of preserved LV function (LV
ejection fraction >0.4). (Level of Evidence: C)
Class III
1. PCI of the infarct-related artery within 48 to 72 h after
thrombolytic therapy without evidence of spontaneous
or provocable ischemia. (Level of Evidence: C)
D. Percutaneous Intervention in Patients With
Prior Coronary Bypass Surgery
Ischemic symptoms recur in 4% to 8% of patients/year
following CABG. Recurrence of symptoms can be attributed
to progression of native vessel coronary disease (5%/year)
and bypass conduit occlusion, particularly SVG failure (7%
in week 1; 15 to 20% in first year; 1 to 2%/year during the
first 5 to 6 years and 3 to 5%/year in years 6 to 10
postoperatively). At 10 years postoperatively, approximately
half of all SVG conduits are occluded and only half of the
remaining patent grafts are free of significant disease. The
requirement for repeat revascularization procedures increases
over time from the initial revascularization, particularly in
younger patients. Although arterial conduits exhibit improved
long-term patency, stenosis or occlusion of these grafts can
occur. Thus, patients with recurrent ischemic symptoms
following CABG may require repeat revascularization due to
diverse anatomic problems.
Risk of repeat surgical revascularization is higher (hospital
mortality 7 to 10%) than initial CABG and both long-term
relief of angina and bypass graft patency are lower than that
of the first procedure. In addition, patients with prior bypass
surgery may have limited graft conduits, impaired LV func-
tion, advanced age, and coexisting medical conditions (cere-
brovascular disease; renal and pulmonary insufficiency)
which may complicate repeat surgical coronary revascular-
ization and prompt consideration for catheter-based interven-
tion.
1. Early Ischemia After CABG
Recurrent ischemia early (,30 days) postoperatively usually
reflects graft failure, often secondary to thrombosis, and may
occur in both saphenous vein and arterial graft conduits.
Incomplete revascularization and unbypassed native vessel
stenoses or stenoses distal to a bypass graft anastomosis may
also precipitate recurrent ischemia. Urgent coronary angiog-
raphy is indicated to define the anatomic cause of ischemia
and to determine the best course of therapy. Emergency PCI
of a focal graft stenosis (venous or arterial) or recanalization
of an acute graft thrombosis may successfully relieve isch-
emia in the majority of patients. Balloon dilation across
suture lines has been accomplished safely within days of
surgery. Adjunctive therapy with abciximab for percutaneous
intervention during the first week following bypass surgery
has been limited but intuitively may pose less risk for
hemorrhage than fibrinolysis. As flow in vein graft conduits
is pressure dependent, intra-aortic balloon pump support
should be considered in the context of systemic hypotension
and/or severe LV dysfunction. If feasible, PCI of both bypass
graft and native vessel offending stenoses should be at-
tempted, particularly if intracoronary stents can be success-
fully deployed.
When ischemia occurs 1 to 12 months following surgery,
the etiology is usually peri-anastomotic graft stenosis. Distal
anastomotic stenoses (both arterial and venous) respond well
to balloon dilation alone and have a more favorable long-term
prognosis than stenoses involving the mid-shaft or proximal
vein graft anastomosis. The immediate results of PCI in
mid-shaft ostial or distal anastomotic vein graft stenoses may
be enhanced by coronary stent deployment.
Percutaneous transluminal coronary angioplasty with or
without stent deployment can be successfully performed in
patients with distal anastomotic stenoses involving the gas-
troepiploic artery bypass graft and in patients with free radial
artery bypass grafts as well. Percutaneous intervention has
also been effective in relieving ischemia for patients with the
stenosis of the subclavian artery proximal to the origin of a
patent left internal mammary artery bypass graft.
2. Late Ischemia After CABG
Ischemia occurring more than 1 year postoperatively usually
reflects the development of new stenoses in graft conduits
and/or native vessels that may be amenable to PCI. Slow-flow
occurs more frequently in grafts having diffuse atheroscle-
rotic involvement, angiographically demonstrable thrombus,
irregular or ulcerative lesion surfaces, and with long lesions
having large plaque volume.
Final patency after PTCA is greater for distal SVG lesions
than for ostial or mid-SVG lesions, and stenosis location
appears to be a better determinant of final patency than graft
age or the type of interventional device used.
Percutaneous intervention for chronic vein graft occlusion
has been problematic. Percutaneous transluminal coronary
angioplasty alone has been associated with high complication
rates and low rates of sustained patency. Favorable results
have been obtained with both local “targeted” and more
prolonged infusion of fibrinolytic agents for nonocclusive
intragraft thrombus. Thrombolytic catheter-based systems
appear to successfully treat SVG thrombosis as well as or
better than thrombolytic agents.
3. Early and Late Outcomes of Percutaneous Intervention
Patients with prior bypass surgery who undergo successful
PCI have a long-term outcome that is dependent on patient
age, the degree of LV dysfunction, and the presence of
multivessel coronary atherosclerosis. The best long-term
results are observed after recanalization of distal anastomotic
stenoses occurring within 1 year of operation. Conversely,
event-free survival is less favorable following angioplasty of
totally occluded SVGs, ostial vein graft stenoses, or grafts
with diffuse or multicentric disease. Coexistent multisystems
disease, the presence of which may have prompted the choice
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of a percutaneous revascularization strategy, may also influ-
ence long-term outcomes in this population.
4. Surgery Versus Percutaneous Reintervention
Aged, diffuse, friable and degenerative SVG disease in the
absence of a patent arterial conduit to the left anterior
descending artery represents a prime consideration for repeat
surgical revascularization. The overall risk of repeat opera-
tion, especially the presence of comorbidities such as con-
comitant cerebrovascular, renal, or pulmonary disease and the
potential for jeopardizing patent, nondiseased bypass con-
duits must be carefully considered. Isolated, friable stenoses
in vein grafts may be approached with primary stenting or the
combination of extraction atherectomy and stenting in an
attempt to reduce the likelihood of distal embolization.
In general, patients with multivessel disease, failure of
multiple SVGs, and moderately impaired LV function, derive
the greatest benefit from the durability provided by surgical
revascularization with arterial conduits. Regardless of repeat
revascularization strategy, risk-factor modification with ces-
sation of smoking and lipid-lowering therapy should be
implemented in patients with prior CABG surgery. An
aggressive lipid-lowering strategy that targets a low-density
lipoprotein level of less than 90 mg/L can be effective in
reducing recurrent ischemic events and the need for subse-
quent revascularization procedures.
Recommendations for PCI With Prior CABG
Class I
1. Patients with early ischemia (usually within 30 days)
after CABG. (Level of Evidence: B)
Class IIa
1. Patients with ischemia occurring 1 to 3 years post-
operatively and preserved LV function with discrete
lesions in graft conduits. (Level of Evidence: B)
2. Disabling angina secondary to new disease in a
native coronary circulation. (If angina is not typical,
the objective evidence of ischemia should be ob-
tained.) (Level of Evidence: B)
3. Patients with diseased vein grafts >3 years following
CABG. (Level of Evidence: B)
Class III
1. PCI to chronic total vein graft occlusions. (Level of
Evidence: B)
2. Patients with multivessel disease, failure or multiple
SVGs, and impaired LV function. (Level of Evi-
dence: B)
E. Use of Adjunctive Technology (Intracoronary
Ultrasound Imaging, Flow Velocity, and Pressure)
The limitations of coronary angiography for diagnostic and
interventional procedures can be reduced by employing
adjunctive technology of intracoronary ultrasound imaging,
flow velocity, and pressure. Information obtained from the
adjunctive modalities of intravascular imaging and physiol-
ogy can improve PCI methods and outcomes.
1. Intravascular Ultrasound Imaging (IVUS)
IVUS is not necessary for all stent procedures. The results of
the French Stent Registry study of 2900 patients treated
without coumadin and without IVUS reported a subacute
closure rate of 1.8%. In the STARS trial, a subacute closure
rate of 0.6% in patients having optimal stent implantation
supports the approach that IVUS does not appear to be
required routinely in all stent implantations. However, the use
of IVUS for evaluating results in high-risk procedures (i.e.,
those patients with multiple stents, impaired TIMI grade flow
or coronary flow reserve, and marginal angiographic appear-
ance) appears warranted.
In the context of published data and growing clinical
experience, the Writing Committee has modified prior rec-
ommendations for the use of IVUS as follows.
Recommendations for Coronary Intravascular
Ultrasound
Class IIa
1. Assessment of the adequacy of deployment of coro-
nary stents, including the extent of stent apposition
and determination of the minimum luminal diame-
ter within the stent. (Level of Evidence: B)
2. Determination of the mechanism of stent restenosis
(inadequate expansion vs. neointimal proliferation)
and to enable selection of appropriate therapy
(plaque ablation vs. repeat balloon expansion). (Lev-
el of Evidence: B)
3. Evaluation of coronary obstruction at a location
difficult to image by angiography in a patient with
a suspected flow-limiting stenosis. (Level of Evi-
dence: C)
4. Assessment of a suboptimal angiographic result fol-
lowing PCI. (Level of Evidence: C)
5. Diagnosis and management of coronary disease follow-
ing cardiac transplantation. (Level of Evidence: C)
6. Establish presence and distribution of coronary cal-
cium in patients for whom adjunctive rotational
atherectomy is contemplated. (Level of Evidence: C)
7. Determination of plaque location and circumferen-
tial distribution for guidance of directional coronary
atherectomy. (Level of Evidence: B)
Class IIb
1. Determine extent of atherosclerosis in patients with
characteristic anginal symptoms and a positive func-
tional study with no focal stenoses or mild CAD on
angiography. (Level of Evidence: C)
2. Preinterventional assessment of lesional character-
istics and vessel dimensions as a means to select an
optimal revascularization device. (Level of Evi-
dence: C)
Class III
1. When angiographic diagnosis is clear and no inter-
ventional treatment is planned. (Level of Evidence: C)
2. Coronary Flow Velocity and Coronary
Vasodilatory Reserve
Coronary flow velocity reserve (CVR), the ratio of hyperemic
to basal flow, reflects flow resistance through the epicardial
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artery and the corresponding myocardial bed. For lesion
assessment, a normal CVR indicates a nonphysiologically
significant stenosis. An abnormal CVR indicates that the
stenosis in the epicardial artery is significant when the
microcirculation is normal, confirmed by measuring rCVR.
Several studies report that deferring PCI of non–flow-limiting
lesions is safe, with ,10% rate of lesion progression.
3. Coronary Artery Pressure and Fractional
Flow Reserve
Fractional flow reserve (FFR) of the myocardium is the ratio
of distal coronary pressure to aortic pressure measured during
maximal hyperemia, which represents the fraction of normal
blood flow through the stenotic artery. The normal FFR value
for all vessels under all hemodynamic conditions, regardless
of the status of microcirculation is 1.0. FFR values ,0.75 are
associated with abnormal stress tests. FFR does not use
measurements in a reference vessel and is thought to be
epicardial lesion-specific.
Reports indicate that a physiologic assessment can deter-
mine whether PTCA alone has achieved a satisfactory result
with 6-month outcome equivalent to that reported with
elective stenting. The DEBATE trial in 224 patients found
that when a final diameter stenosis ,35% and an excellent
physiologic result (CVR .2.5) were obtained after PTCA
(44/224 patients), the intermediate-term (6 months) target
lesion revascularization and angiographic restenosis rates
were 16%. Similar data have been reported for FFR. The
application of coronary physiologic adjunctive modalities can
facilitate decision making for moderate lesions, the appropri-
ateness of PTCA, and the use of provisional stenting.
Recommendations for Intracoronary Physiologic
Measurements (Doppler Ultrasound, FFR)
Class IIa
1. Assessment of the physiological effects of intermedi-
ate coronary stenoses (30 to 70% luminal narrow-
ing) in patients with anginal symptoms. Coronary
pressure or Doppler velocimetry may also be useful
as an alternative to performing noninvasive func-
tional testing (e.g., when the functional study is
absent or ambiguous) to determine whether an
intervention is warranted. (Level of Evidence: B)
Class IIb
1. Evaluation of the success of percutaneous coronary
revascularization in restoring flow reserve and to
predict the risk of restenosis. (Level of Evidence: C)
2. Evaluation of patients with anginal symptoms with-
out an apparent angiographic culprit lesion. (Level
of Evidence: C)
Class III
1. Routine assessment of the severity of angiographic
disease in patients with a positive, unequivocal non-
invasive functional study. (Level of Evidence: C)
VI. Management of Patients Undergoing PCI
A. Experience With New Technologies
The introduction of coronary stents and atherectomy devices
has broadened the scope of patients that can be approached by
PCI beyond those that could be safely treated by PTCA alone.
1. Acute Results
Significant reduction in the acute complication rate for PTCA
has resulted from the adjunctive use of GP receptor IIb/IIIa
blockers, which have been shown to reduce abrupt closure
and periprocedural MI rates compared to placebo. Improved
acute outcomes (in terms of abrupt closure rates and reduced
target lesion residual diameter stenosis) have also been seen
with the use of coronary stents, DCA, and adjunctive rota-
tional atherectomy.
2. Late-Term Results
PCI devices offer the possibility of lower restenosis com-
pared to PTCA in the native coronary circulation. Lower
restenosis rates have been demonstrated for balloon-
expandable slotted tubular stents in large ($3 mm) native
coronary arteries but are variable depending on lesion length
for SVG lesions. Initial trials of DCA showed no benefit
compared to PTCA for elective single-lesion treatment.
Despite the improvement in acute results seen for rotational
atherectomy and excimer laser, there is no evidence that these
devices improve the late outcomes in lesions than can be
feasibly treated by PTCA or stenting alone.
B. Antiplatelet and Antithrombotic Therapies and
Coronary Angioplasty
1. Aspirin, Ticlopidine, Clopidogrel
Aspirin reduces the frequency of ischemic complications
after coronary angioplasty. Although the minimum effective
aspirin dosage in the setting of coronary angioplasty has not
been established, an empiric dose of aspirin, 80 to 325 mg,
given at least 2 h before PCI is generally recommended.
While other antiplatelet agents have similar antiplatelet ef-
fects to aspirin, only the thienopyridine derivatives, ticlopi-
dine and clopidogrel, have been routinely used as alternative
antiplatelet agents in aspirin-sensitive patients during coro-
nary angioplasty.
Ticlopidine has a number of important side effects. The
most severe side effect is severe neutropenia, occurring in
approximately 1% of patients. Clopidogrel, 300 mg loading
dose followed by 75 mg daily, may be used as an alternative
to ticlopidine in patients undergoing stent placement. A
number of nonrandomized trials and a randomized trial have
failed to show a difference in the clinical outcomes among
patients treated with ticlopidine and clopidogrel after stent
placement. A small number of cases of thrombocytopenia
purpura have been reported in patients treated with clopi-
dogrel; therefore, patients should be monitored during treat-
ment for occurrence of this untoward effect.
2. GP IIb/IIIa Inhibitors
The binding of fibrinogen and other adhesive proteins to
adjacent platelets by means of the GP IIb/IIIa receptor serves
as the “final common pathway” of platelet-thrombus forma-
tion and can be effectively attenuated by GP IIb/IIIa antag-
onists. These agents have reduced the frequency of ischemic
complications after coronary angioplasty.
Based on the numerous trials to date (Fig. 1), intravenous
GP IIb/IIIa receptor inhibitors should be considered in pa-
tients undergoing coronary angioplasty, particularly those
with unstable angina or with other clinical characteristics of
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high-risk. There is no consistent evidence that the GP IIb/IIIa
inhibitors reduce the frequency of late restenosis in the
nondiabetic patient. In EPISTENT, diabetic patients who
received abciximab therapy in conjunction with stent deploy-
ment had a 51% reduction in target-vessel revascularization
at 6 months. This trial is the only one that has shown a
reduction in target-vessel revascularization in the diabetic
group. It will be important to determine if supporting evi-
dence is found from other trials using this agent and other GP
IIb/IIIa antagonists.
3. Heparin
Heparin is an important component for PCI, despite dosing
uncertainties and an unpredictable therapeutic response with
the unfractionated preparation. Higher levels of anticoagula-
tion with heparin are roughly correlated with therapeutic
efficacy in the reduction of complications during coronary
angioplasty, albeit at the expense of bleeding complications at
very high levels of heparin dosing. It appears that weight-
adjusted heparin dosing may provide a clinically superior
anticoagulation method over fixed heparin dosing, although
definitive studies are lacking.
Some patients with unstable angina are treated with low-
molecular-weight heparin (LMWH) prior to coronary angio-
plasty. Anticoagulation monitoring is not routinely possible
with LMWH, and conventional dosages of unfractionated
heparin are currently recommended. Conventional ACT mon-
itoring methods may underestimate the true degree of
periprocedural anticoagulation with LMWH. Use of LMWH
as the sole anticoagulant during PCI is not supported at this
time in the absence of absolute or relative contraindications to
unfractionated heparin, although data from clinical trials of
these agents administered alone or in conjunction with GP
IIb/IIIa blockade are forthcoming.
In those patients who do not receive GP IIb/IIIa inhibitors,
sufficient unfractionated heparin should be given during
coronary angioplasty to achieve an ACT of 250 to 300 s with
the HemoTec device and 300 to 350 s with the Hemochron
device.
The unfractionated heparin bolus should be reduced to 50
to 70 IU/kg when GP IIb/IIIa inhibitors are given in order to
achieve a target ACT of 200 s using either the HemoTec or
Hemochron device.
C. Post-PCI Management
Following PCI, in-hospital care should focus on monitoring
the patient for recurrent myocardial ischemia, achieving
hemostasis at the catheter insertion site, and detecting and
preventing contrast-induced renal failure. Attention should
also be directed toward implementing appropriate secondary
atherosclerosis prevention programs. The patient should un-
derstand and adhere to recommended medical therapies and
behavior modifications known to reduce subsequent morbid-
ity and mortality from coronary heart disease.
Most patients can be safely discharged from the hospital
within 24 h after an uncomplicated elective PCI. Special
skilled nursing units have been developed by many institu-
tions to facilitate post-PCI management. Specific protocols
for sheath removal, continuation of anticoagulation or antiplate-
let therapies, and observation for recurrent myocardial ischemia/
infarction and contrast-induced renal failure are of particular
assistance in ensuring appropriate outcomes during this period.
Pilot studies suggest that selected patients may be discharged on
the same day after PCI especially when the procedure is
performed by the percutaneous radial or brachial approach.
However, confirmation by larger studies is necessary prior to
widespread endorsement of this strategy.
1. Post-Procedure Evaluation of Ischemia
After PCI, chest pain may occur in as many as 50% of
patients. ECG evidence of ischemia identifies those with
significant risk for acute vessel closure. When angina pectoris
Figure 1. Death or nonfatal MI outcomes at 30 days in 10 randomized, placebo-controlled trials of GP IIb/IIIa blockers. Data and acro-
nyms from references 30–39 (these numbers coincide with references in the original article). Risk ratio with 95% CI, size of RR box
being proportional to total sample size. Frequency of death or nonfatal MI in columns 4 and 5. Overall (all 10 trials) benefit of GP IIb/IIIa
blockade highly significant (RR 5 0.79 [95% CI 0.73–0.85; p , 1029). GP 5 glycoprotein; OR 5 odds ratio; CI 5 confidence interval;
MI 5 myocardial infarction. Reproduced with permission from Topol EJ, et al. Lancet 1999;353:227–31.
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or ischemic ECG changes occur after PCI, the decision to
proceed with further interventional procedures, CABG sur-
gery, or medical therapy should be individualized based on
factors such as hemodynamic stability, amount of myocar-
dium at risk, and the likelihood that the treatment will be
successful.
Patients with renal dysfunction and diabetes should be
monitored for contrast-induced nephropathy. In addition,
those patients receiving higher contrast loads or a second
contrast load within 72 h should have renal function assessed.
Whenever possible, nephrotoxic drugs (certain antibiotics,
nonsteroidal anti-inflammatory agents, and cyclosporine) and
metformin (especially in those with pre-existing renal dys-
function) should be withheld for 24 to 48 h prior to perform-
ing PCI and for 48 h afterwards.
2. Risk-Factor Modifications
All patients should be instructed about necessary behavior
and risk-factor modification and the appropriate medical
therapies for the secondary prevention of atherosclerosis prior
to leaving the hospital. The interventional cardiologist should
emphasize the importance of these measures directly to the
patient as failure to do so may suggest that secondary
prevention therapies are not necessary. The interventional
cardiologist should interact with the primary care physician to
assure that necessary secondary prevention therapies are
initiated and maintained. Secondary prevention measures are
an essential part of long-term therapy because they can
reduce future morbidity and mortality associated with the
atherosclerotic process.
Depending on the risk factors and contraindications present,
advice should include aspirin therapy, hypertensive control,
diabetic management, aggressive control of serum lipids to a
target LDL goal ,100 mgm/dl following AHA guidelines,
abstinence from tobacco use, weight control, regular exercise,
and ACE inhibitor therapy as recommended in the AHA/ACC
consensus statement on secondary prevention.
3. Exercise Testing After PCI
Although restenosis remains the major limitation of PCI,
symptom status is an unreliable index to development of
restenosis with 25% of asymptomatic patients documented as
having ischemia on exercise testing.
Because myocardial ischemia, whether painful or silent,
worsens prognosis, some authorities have advocated routine
testing. However, the ACC/AHA practice guidelines for
exercise testing favor selective evaluation in patients consid-
ered to be at particularly high risk (e.g., patients with
decreased LV function, multivessel CAD, proximal left
anterior descending disease, previous sudden death, diabetes
mellitus, hazardous occupations, and suboptimal PCI results).
The exercise ECG is an insensitive predictor of restenosis,
with sensitivities ranging from 40 to 55%, significantly less
than those obtainable with SPECT or exercise echocardiog-
raphy. This lower sensitivity of the exercise ECG and its
inability to localize disease limits its usefulness in patient
management both before and after PCI. For those reasons,
stress imaging is preferred to evaluate symptomatic patients
after PCI. If the patient’s exertional capacity is significantly
limited, coronary angiography may be more expeditious to
evaluate symptoms of typical angina. Exercise testing after
discharge is helpful for activity counseling and/or exercise
training as part of cardiac rehabilitation. Neither exercise
testing nor radionuclide imaging is indicated for the routine,
periodic monitoring of asymptomatic patients after PCI with-
out specific indications.
VII. Special Considerations
A. Ad-Hoc Angioplasty—PCI at the Time of
Initial Cardiac Catheterization
Ad-hoc coronary intervention is PCI performed at the same
time as diagnostic cardiac catheterization. Since the last
revision of these Guidelines, there has been an increase in
ad-hoc interventions with reported incidence ranging from 52
to 83%.
Ad-hoc coronary intervention is particularly suitable for
patients with clinical evidence of restenosis 6 to 12 months
following the initial procedure, patients undergoing primary
angioplasty for MI, and patients with refractory unstable
angina in need of urgent revascularization. Ad-hoc PCI
should be performed only in a well-informed patient, partic-
ularly in the setting of single-vessel disease without morpho-
logic features predictive of an adverse outcome, when it is
clear that this treatment strategy is the best alternative. This
committee endorses the recommendations from the Society
for Cardiac Angiography and Interventions that ad-hoc PCI
be individualized and not be a standard or required strategy
for all patients.
B. PCI in Cardiac Transplant Patients
Although high procedural success can be achieved and PCI
may be applied in a selected cardiac transplant population
with comparable success and complication rates to the routine
patient population, it remains unknown whether PCI prolongs
allograft survival. Coronary stenting in cardiac allograft
vascular disease has been performed in small numbers of
patients with favorable results. Long-term survival effects
remain under examination.
C. Management of Clinical Restenosis
Although atheroablation devices have been developed in an
attempt to lower the second restenosis risk in patients, none
has shown an incremental benefit over PTCA. It is recom-
mended that patients who develop restenosis following an
initially successful PTCA be considered for repeat PCI with
stent placement. Factors that may influence this decision
include the technical difficulty of the initial procedure, the
potential for the lesion to be treated successfully with a stent,
and the severity and extent of the restenotic process. Each
time restenosis recurs, consideration should be given to
alternate methods of revascularization, particularly CABG
surgery, as well as continued medical therapy.
D. Restenosis After Stent Implantation
(In-stent Restenosis)
Intracoronary vascular radiation for in-stent restenosis with
either gamma or beta radiation is the most promising therapy
for in-stent restenosis at this time, reducing the chance for
repeat restenosis by other methods from 50 to 60% to 25 to
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35%. In the absence of vascular radiation for in-stent resten-
osis, there appears to be little difference in outcome between
angioplasty alone as compared to combination with ablative
techniques.
E. Cost-Effectiveness Analysis for PCI
While there is no established cost-effectiveness ratio thresh-
old, cost-effectiveness ratios of ,$20,000 per QALY (such
as seen in the treatment of severe diastolic hypertension or
cholesterol lowering in patients with ischemic heart disease)
are considered highly favorable and consistent with well
accepted therapies.
In patients with severe angina, normal LV function, and
single-vessel disease of the left anterior descending artery, the
cost-effectiveness ratio for PTCA, directional coronary
atherectomy, or coronary stenting that can be expected to
provide .90% success rate with ,3% major acute compli-
cation rate is very favorable (,$20,000 per QALY) com-
pared to medical therapy. In patients with 3-vessel coronary
disease who have comorbidities that increase operative risk
for CABG surgery, PCI that is felt to be safe and feasible is
reasonably acceptable ($20,000 to $60,000 per QALY). In
patients in the post-MI setting, a strategy of routine,
nonsymptom-driven coronary, angiography and PCI per-
formed for critical (.70% diameter stenosis) culprit coronary
lesions amenable to PTCA or stenting has been proposed to
be reasonably cost-effective in many subgroups.
In patients with symptomatic angina or documented isch-
emia and 3-vessel coronary disease, for which bypass surgery
can be expected to provide full revascularization and an acute
complication rate of less than 5%, the cost-effectiveness of
PCI is not well established. Although PTCA for 2- and
3-vessel coronary disease appears to be as safe, but initially
less expensive, than CABG surgery, the costs of PTCA
converge towards the higher costs of bypass surgery after 3 to
5 years. Thus, while PTCA or CABG surgery has been shown
to be cost-effective when compared to medical therapy, there
is no evidence for incremental cost-effectiveness of PTCA
over bypass surgery for 2- or 3-vessel coronary disease in
patients who are considered good candidates for both proce-
dures. For patients with 1- or 2-vessel coronary disease who
are asymptomatic or have only mild angina, without docu-
mented left main disease, the estimated cost-effectiveness
ratios for PCI are greater than $80,000 per QALY compared
with medical therapy, and are thus considered less favorable.
Because CEA research is new in the field of percutaneous
coronary intervention, CEA results are limited. The Commit-
tee underscores the need for cost containment and careful
decision making regarding the use of PCI strategies.
VIII. Future Directions
An exciting arena of active investigation relates to methods of
distal protection of the coronary vascular bed during PCI. It is
now recognized that distal embolization is an important
contributor to complications in patients undergoing SVG
intervention. Distal embolization is often due to dislodgement
of large, macroparticles from the friable graft, rather than
release of platelet-mediated aggregates. This complication
can be prevented by the use of distal occlusion balloons, such
as the PercuSurge Guardwire, or with the use of distal filters
that trap the debris and remove it from the distal circulation.
A number of filter devices are currently undergoing clinical
evaluation, particularly in saphenous vein graft disease and
during carotid intervention.
Restenosis has also remained a vexing problem, despite the
benefits achieved with stent implantation. Novel therapies
have been developed, such as the application of therapeutic
ultrasound, photodynamic therapy, and systemic administra-
tion of the anti-inflammatory agent tranilast. An area of active
investigation involves the use of balloon-expandable stents
coated with rapamycin, paclitaxol, or its derivative. The local
delivery of these agents has shown promise in early clinical
trials, and longer-term studies are currently underway.
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